Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
PT2385 is a hypoxia inducible factor-2alpha (EPAS1, HIF2A) inhibitor that suppresses expression of HIF2A target genes, resulting in anti-tumor activity (J Clin Oncol 34, 2016 (suppl; abstr 2506)).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PT2385||PT2385 is a hypoxia inducible factor-2alpha (EPAS1, HIF2A) inhibitor that leads to dissociation of HIF-2 complexes, thereby suppressing expression of HIF2A target genes, and potentially resulting in antitumor activity (PMID: 31727677).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||clear cell renal cell carcinoma||not applicable||PT2385||Phase I||Actionable||In a Phase I trial, treatment with PT2385 in patients with renal clear cell carcinoma resulted in a disease control rate of 66% (33/50), including one patient with a complete response, six patients achieving a partial response, and twenty-six patients with stable disease, and led to a progression-free survival of more than 14 months in 25% of patients (PMID: 29257710).||29257710 detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03108066||Phase II||PT2385||PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma||Active, not recruiting|
|NCT03216499||Phase II||PT2385||HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma||Completed|
|NCT02293980||Phase I||PT2385 Nivolumab + PT2385||A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma||Active, not recruiting|